ClinicalTrials.gg
CompletedNCT03332342Updated May 17, 2019

Closed Eye Neutrophils in Dry Eye Disease

An interventional study of Eye wash in Dry Eye and Ocular Inflammation, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-17.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this prospective study is to evaluate different inflammatory cells that accumulate on the ocular surface, during sleep, and how these cells may contribute to dry eye disease. This study will involve at-home self-collection of tears using an eye wash method with sterile saline solution. While a diagnostic technique, the eye wash may also have a therapeutic benefit in dry eye sufferers, which will be assessed in the second phase of this project.

Read the detailed description

Every night during sleep, there is an influx of white blood cells on to the surface of the eye. These cells likely perform a protective function, but it is also possible that their dysregulation could lead to disease. Using a larger cohort, our investigation hopes to better understand the function of these cells and their potential to be linked to dry eye disease. Further, the way in which these cells are collected, using an at-home self-collection of tears using an eye wash method with sterile saline solution, immediately upon awakening, could potentially provide relief to dry eye sufferers if performed on a daily basis.

02

Conditions studied

  • Dry Eye
  • Ocular Inflammation

Keywords

  • dry eye disease
  • tears
  • inflammation
  • ocular surface
03

In context

Dry Eye Syndromes

1,366 studies on the registry are indexed under Dry Eye Syndromes; 207 are open to participants now.

This study's enrollment of 153 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.

Browse Dry Eye Syndromes studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,421 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • able to understand and sign an and HIPAA privacy document
  • greater than 18 years of age at time of informed consent
  • able and willing to follow protocol instructions, including performing at-home washes of the ocular surface and subsequent delivery of those samples to campus on a regular basis
  • must be willing to have blood drawn

Exclusion criteria

Exclusion Criteria:

  • contact lens wear within past three months
  • current consumption of cigarettes or tobacco, including e-cigarettes
  • participation in any drug studies within 30 days of
  • pregnancy, by self-report
  • active ocular infection or inflammation
  • any refractive surgery within the past year
  • any present Accutane (Isotretinoin) use
  • any medication usage that, in the investigator's opinion, could be expected to interfere with the study, such as current use of topical , Restasis, or Xiidra
  • have any uncontrolled systemic disease, that in the investigator's opinion could be expected to interfere with the study, for example, conditions associated with dry eye disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Daily rinse of ocular surface

    Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed daily.

    Other: Eye wash

  • Active comparator
    Weekly rinse of ocular surface

    Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed weekly.

    Other: Eye wash

  • Experimental
    Occasional rinse of ocular surface

    Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed on two separate occasions

    Other: Eye wash

Interventions

  • OtherEye wash

    Research subjects will perform a wash of their ocular surface with phosphate buffered saline

06

What researchers measure

Primary outcomes

  1. Comfort assessment using the dry eye questionnaire

    Mean change from baseline in comfort following daily ocular surface washes

    Time frame: Baseline to 4 weeks

  2. Comfort assessment using the ocular surface disease index

    Mean change from baseline in comfort following daily ocular surface washes

    Time frame: Baseline to 4 weeks

Secondary outcomes

  1. Repeatability of diagnostic in measuring leukocyte count

    Repeatability of the eye wash in terms of leukocyte count, as measured by flow cytometry

    Time frame: Baseline to 4 weeks

  2. Repeatability of diagnostic in measuring leukocyte phenotype

    Repeatability of the eye wash in terms of leukocyte phenotype, as measured by flow cytometry

    Time frame: Baseline to 4 weeks

07

Study locations

1 site
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Dec 2018, 13 months.

Of 199 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 13 months is close to that.

Counting every sponsor, half of 312 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2017
First posted
Nov 6, 2017
StartActual
Nov 8, 2017
Primary completionActual
Dec 12, 2018
CompletionActual
May 14, 2019
Last update
May 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03332342
Collaborators
Allergan Sales, LLC
Responsible party
Kelly Nichols (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Nov 6, 2017
Start date
Nov 8, 2017
Primary completion
Dec 12, 2018
Completion
May 14, 2019
Last update
May 17, 2019

Study contacts

Kelly K Nichols, OD MPH PhD
principal investigator · UAB School of Optometry

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion